These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2487171)

  • 21. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
    Weiss E; Kemmler G; Fleischhacker WW
    Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
    [No Abstract]   [Full Text] [Related]  

  • 22. Visual fixation deficits and evidence of cognitive impairment in schizophrenia.
    Rosse RB; Malhotra AK; Kim SY; Deutsch SI
    Biol Psychiatry; 1992 Feb; 31(4):412-4. PubMed ID: 1558904
    [No Abstract]   [Full Text] [Related]  

  • 23. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 25. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging.
    Friedman JI; Harvey PD; Coleman T; Moriarty PJ; Bowie C; Parrella M; White L; Adler D; Davis KL
    Am J Psychiatry; 2001 Sep; 158(9):1441-8. PubMed ID: 11532729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of response to haloperidol dose reduction by Span of Apprehension measures for treatment-refractory schizophrenic patients.
    Green MF; Mintz J; Bowen L; Marshall BD; Kuehnel TG; Hayden JL; Liberman RP
    Am J Psychiatry; 1993 Sep; 150(9):1415-6. PubMed ID: 8352355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
    McDermott BE; Sautter FJ; Garver DL
    Psychiatry Res; 1991 Apr; 37(1):97-103. PubMed ID: 1862165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neurological soft signs in early onset schizophrenia].
    Bourgou Gaha S; Halayem Dhouib S; Amado I; Bouden A
    Encephale; 2015 Jun; 41(3):209-14. PubMed ID: 24854724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
    Bartkó G; Herczeg I; Békésy M
    J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
    Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
    Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 38. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.
    Hagger C; Buckley P; Kenny JT; Friedman L; Ubogy D; Meltzer HY
    Biol Psychiatry; 1993 Nov; 34(10):702-12. PubMed ID: 8292674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
    McEvoy JP; Hogarty GE; Steingard S
    Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
    Lindenmayer JP; Iskander A; Park M; Apergi FS; Czobor P; Smith R; Allen D
    J Clin Psychiatry; 1998 Oct; 59(10):521-7. PubMed ID: 9818633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.